Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Video

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma (NHL).

A single-arm, open-label, phase 1 expansion trial (NCT03019055) evaluated the safety and feasibility of anti-CD20 and anti-CD19 CAR T-cell therapy in patients with relapsed/refractory CD19/CD20​-positive B-cell malignancies, Shah says.

Currently, the majority of available CAR T-cell therapies in B-cell malignancies target CD19, explains Shah. However, CD20 has been a mainstay target in NHL for many years. For example, rituximab (Rituxan), a CD20-directed monoclonal antibody, is a widely utilized therapy in B-cell NHL. As such, dual-targeting CAR T-cell therapies have the potential to engage the tumor at CD19 and CD20 and minimize the risk of antigen escape by CD19 downregulation. Antigen escape is a known mechanism of resistance to single-target CAR T-cell therapy, Shah concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.